Amniotic membrane therapy represents a breakthrough in biological ophthalmology, utilising the innermost layer of the human placenta—the same tissue that protects and nurtures developing babies throughout pregnancy. This remarkable tissue has been used in medicine for over a century, but modern processing and preservation techniques have transformed it into a sophisticated therapeutic tool for eye care.
The amniotic membrane is uniquely positioned in nature to provide optimal healing properties. During pregnancy, it serves as a protective barrier whilst facilitating nutrient transfer and waste removal. These same properties make it ideal for treating damaged ocular surfaces. The membrane contains a rich mixture of growth factors including epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and basic fibroblast growth factor (bFGF), all of which play crucial roles in tissue repair and regeneration.
What makes amniotic membrane particularly valuable in ophthalmology is its ability to reduce inflammation whilst simultaneously promoting healing. Unlike synthetic materials or traditional bandages, the amniotic membrane actively participates in the healing process. It suppresses the immune response that can lead to scarring, encourages the migration of healthy epithelial cells, and provides a scaffold for new tissue formation. This biological bandage is completely biocompatible, gradually integrating with the patient's own tissue without causing rejection or adverse reactions.
Amnio-Patch™ is Akriti Ophthalmic's advanced solution, representing a significant leap in regenerative ophthalmology. It leverages the inherent healing properties of dehydrated amniotic membrane to provide superior therapeutic outcomes for various ocular surface conditions.
Amnio-Patch™ can be stored at room temperature, eliminating the need for special freezers and complex cold chain logistics, making it readily available for immediate clinical use.
An impressive 5-year shelf life ensures extended usability and reduces waste, contributing to cost-effectiveness and convenient inventory management.
Designed for user-friendliness, Amnio-Patch™ offers a straightforward application protocol, simplifying procedures for ophthalmologists and enhancing patient comfort.
This innovative dehydrated amniotic membrane solution provides significant advantages over cryopreserved alternatives. Its stability at room temperature not only simplifies storage but also ensures that the product is always ready for urgent cases, where time-sensitive intervention can preserve vision. The long shelf life also reduces logistical burdens and potential stock-outs in clinical settings.
- Persistent epithelial defects
- Chemical and thermal burns
- Neurotrophic keratopathy
- Post-surgical wounds
- Recurrent corneal erosions
- Conjunctival defects
The professional medical imagery demonstrates the precise application of Amnio-Patch™, showcasing its seamless integration into surgical and clinical procedures. The visual elements emphasize both the convenience and effectiveness of the product in a sterile, professional medical setting.
The Amnio-Disc™ product line advances targeted ocular surface therapy, giving surgeons precise control over treatment delivery. Available in three calibrated sizes (6.00 mm, 8.00 mm, and 10.00 mm, 12.00mm, 14.00mm, 16.00 mm ), these dehydrated amniotic membrane discs are engineered for optimal placement on corneal lesions of varying dimensions. The disc format offers key advantages over traditional membrane sheets, including standardized sizing for consistent dosing, easier handling, and improved stability upon positioning.
Precisely sized for smaller corneal lesions and targeted treatment. Ideal for central corneal ulcers, small epithelial defects, and focal limbal stem cell deficiency. This compact size ensures minimal healthy tissue overlap while providing complete coverage of the affected area.
Designed for larger corneal injuries and extensive surface damage. Perfect for treating peripheral corneal ulcers, post-pterygium excision sites, and broader areas requiring regenerative support. It offers enhanced coverage without compromising the visual axis when properly positioned.
Provides maximal coverage for extensive defects and reconstructive procedures. Recommended for total limbal stem cell deficiency, large chemical burns, and cases requiring significant epithelial resurfacing. This size ensures comprehensive coverage for diffuse pathology.
Each Amnio-Disc™ undergoes a sophisticated dehydration process, preserving the membrane's biological activity and creating a stable, shelf-ready product. This technique maintains the structural integrity of the extracellular matrix and protects essential growth factors and cytokines for healing. Upon contact with the tear film or surgical irrigation, the disc rapidly rehydrates, conforming to corneal contours and establishing intimate contact with underlying tissue.
Amnio-Disc™ has extensive and well-documented clinical applications. For bacterial or fungal corneal ulcers, the disc provides both mechanical protection and biological support, accelerating healing and minimizing scarring. Following pterygium excision, it covers the bare sclera, significantly reducing recurrence rates compared to bare sclera techniques. In patients with limbal stem cell deficiency, the disc supports re-establishment of a healthy corneal epithelium by providing a scaffold for stem cell migration and differentiation.
Surgical integration of Amnio-Disc™ is remarkably straightforward, with clear protocols for both suture fixation and fibrin glue application. The disc's uniform thickness and consistent quality ensure predictable handling, enabling surgeons to refine placement and fixation techniques. Post-operative monitoring is simplified by its transparency, allowing visualization of the underlying healing process without graft removal or disruption.
Amnio-Patch-C represents Akriti Ophthalmic's commitment to innovation, offering a premium cryopreserved amniotic membrane product engineered for complex ocular surface reconstruction. This advanced patch integrates superior features for challenging cases, ensuring optimal healing outcomes.
Amnio-Patch-C is a premium cryopreserved amniotic membrane product with a precise 50 micron thickness. It is available in multiple sizes, ranging from 1cm x 1cm to 10cm x 6cm, allowing for tailored application to various defect sizes.
Specifically designed for complex ocular surface reconstruction, Amnio-Patch-C offers superior adhesion and durability. These enhanced properties ensure stable attachment and extended effective treatment periods, even in challenging anatomical locations.
The premium pricing of Amnio-Patch-C reflects its advanced processing and enhanced capabilities, making it ideal for cases requiring extensive tissue regeneration where uncompromising quality is paramount.
Amnio-Patch-C provides significant clinical advantages across a range of severe ocular conditions:
Supports healing and reduces inflammation in severe herpetic infections.
Provides structural support and promotes regeneration in critical corneal defects.
Offers a biological scaffold to aid healing in refractory fungal infections.
Enhances re-epithelialization and nerve regeneration in challenging neurotrophic cases.
Provides a protective barrier and delivers healing factors to combat aggressive infections.
Assists in post-excision reconstruction and reduces recurrence risk.
Effectively used with suturing or fibrin glue to prevent recurrence and promote smooth ocular surface healing.
Amnio-Patch-C reflects Akriti Ophthalmic's dedication to providing cutting-edge solutions derived from extensive collaboration with leading ophthalmic surgeons. This product addresses critical clinical needs with unparalleled biological efficacy and patient safety.
The Amnio-ring represents a significant advancement in ocular surface repair, functioning as an innovative contact lens-like carrier system designed to deliver and secure the therapeutic benefits of the amniotic membrane. This breakthrough technology transforms the application of regenerative therapy, making it more efficient and patient-friendly.
Eliminates the need for sutures, streamlining the procedure and reducing potential irritation.
Designed to fit naturally on the eye, significantly improving comfort compared to traditional methods.
Ensures consistent contact between the amniotic membrane and the ocular surface for optimal healing.
The Amnio-ring works through a unique combination of gentle suction and capillary action, which holds the therapeutic amniotic membrane securely in place on the ocular surface without the need for invasive suturing. This mechanism allows for stable and continuous delivery of growth factors and anti-inflammatory agents directly to the damaged tissue.
Designed for simple, non-surgical placement and removal, making the procedure quick and efficient for clinicians.
By promoting a stable healing environment, the Amnio-ring contributes to faster and more predictable patient recovery.
Its clear design allows for easy monitoring of the underlying ocular surface throughout the healing process.
Compared to traditional membrane grafts that often require complex surgical application and can cause discomfort, the Amnio-ring offers a vastly improved patient experience. Its innovative design, emphasizing both ease of use and patient comfort, marks a significant step forward in ocular surface regeneration.
Natarajan MacuSeal™, an innovation championed by Dr. Sundaram Natarajan and powered by Akriti Ophthalmic, marks a paradigm shift in retinal surgery. Unlike general ocular surface solutions, MacuSeal™ is specifically engineered as a biologically active, dehydrated amniotic membrane, meticulously sourced from the innermost layer of the placenta. This specialized membrane is designed to address critical needs within the delicate environment of the retina, offering unparalleled support for complex surgical interventions and promoting optimal healing outcomes.
Actively reduces inflammation and prevents scar tissue formation, crucial for maintaining retinal function post-surgery.
Accelerates the regeneration of delicate retinal epithelial cells, supporting faster and more complete recovery.
Minimizes immune response, allowing for seamless integration and reduced risk of rejection in the sensitive ocular environment.
Provides a natural biological matrix that encourages cellular migration, proliferation, and differentiation, essential for tissue repair.
Ideal for challenging cases including refractory, large-diameter, or high-myopia-associated macular holes, providing a robust scaffold for closure and regeneration.
Serves as a crucial adjunct in complex retinal detachments, particularly those complicated by Proliferative Vitreoretinopathy (PVR), giant retinal tears, or defects in the posterior pole, enhancing reattachment and reducing recurrence.
Natarajan MacuSeal™ is available in multiple sizes to accommodate diverse surgical needs: 500, 1000, 1500, and 2000 micron diameters. It also offers flexibility in thickness, available in both 50 and 100 micron options, allowing surgeons to select the most appropriate membrane for specific case requirements. The future potential of MacuSeal™ extends into advanced applications, including stem cell enhancement and cutting-edge bioengineering, promising further breakthroughs in retinal care.
Clinical feedback highlights its precision and effectiveness, positioning Natarajan MacuSeal™ as a leading solution for specialized retinal surgery.
At Akriti Ophthalmic, quality and safety are not merely regulatory requirements—they are fundamental principles that guide every aspect of our operations. From donor selection through final product delivery, we maintain rigorous standards that exceed international regulatory requirements. Our commitment to excellence ensures that every amniotic membrane product reaching clinicians and patients represents the highest achievable standards of purity, potency, and safety.
All tissue donors undergo comprehensive medical history review and serological testing that surpasses FDA and international standards. Only healthy donors undergoing elective caesarean deliveries are considered, with multiple screening checkpoints ensuring tissue integrity and safety.
Placental tissue collection follows strict aseptic techniques in accredited surgical facilities. Our trained personnel ensure proper handling from the moment of delivery, maintaining cold chain integrity and documenting every step of the collection process.
Manufacturing occurs in cGTP-compliant facilities with validated processing procedures. Each batch undergoes multiple quality assessments, including microbiological testing, endotoxin evaluation, and verification of structural integrity throughout processing.
Final products are subjected to extensive quality control testing, including sterility verification, growth factor activity assays, and physical property assessments. No product is released without complete documentation and approval from our quality assurance team.
Sterile packaging systems maintain product integrity throughout the distribution chain. Our packaging design has been validated to preserve product characteristics across varying environmental conditions whilst ensuring ease of use in clinical settings.
Akriti Ophthalmic operates under comprehensive regulatory oversight, maintaining registrations and certifications from multiple international regulatory bodies. Our facilities are regularly inspected and our processes continuously audited to ensure ongoing compliance.
- FDA Current Good Tissue Practice (cGTP) compliance (under processs)
- ISO 13485 Quality Management System certification
- Regular third-party audits and inspections
- Comprehensive traceability systems
- Adverse event monitoring and reporting
- Continuous quality improvement programmes
Our quality management system encompasses every stage of product development and manufacturing, from initial research through post-market surveillance. We maintain detailed batch records that provide complete traceability from donor to end user, enabling rapid response should any quality concerns arise. This meticulous documentation also supports our continuous improvement initiatives, allowing us to refine processes based on accumulated data and emerging best practices.
Every donor undergoes comprehensive medical evaluation and serological testing before tissue acceptance
Extended stability ensures product availability when needed without compromise to biological activity
Unwavering commitment to safety means we never release product that doesn't meet our exacting standards
Beyond regulatory compliance, we invest heavily in ongoing research to better understand the biological mechanisms underlying our products' effectiveness. This research not only enhances our manufacturing processes but also contributes to the broader scientific understanding of amniotic membrane therapy, benefiting the entire ophthalmic community. We regularly publish our findings in peer-reviewed journals and present at international conferences, reinforcing our position as thought leaders in regenerative ophthalmology.
We invite you to explore the full potential of regenerative ocular therapy through Akriti Ophthalmic's comprehensive product portfolio. Whether you're an experienced corneal specialist seeking to enhance your therapeutic options or a general ophthalmologist looking to better serve patients with challenging ocular surface conditions, our amniotic membrane solutions offer proven effectiveness backed by rigorous science and unwavering quality commitment.
Visit our website at www.akritiophthalmic.com to access detailed technical specifications, clinical study results, surgical technique videos, and case studies demonstrating real-world outcomes across diverse patient populations and clinical scenarios.
Access our extensive library of educational materials, including peer-reviewed publications, webinar recordings, and step-by-step application guides. Stay current with the latest developments in amniotic membrane therapy through our regularly updated clinical insights section.
Join thousands of eye care professionals worldwide who are transforming patient outcomes through regenerative ocular therapies. Connect with colleagues, share experiences, and learn from leading experts through our international professional network and regular continuing education programmes.
Integrating new therapeutic modalities into clinical practice requires more than just product availability—it demands comprehensive support and education. Akriti Ophthalmic is committed to ensuring your success through:
- One-on-one product training sessions with experienced clinical specialists
- Customised integration protocols tailored to your practice workflow
- Ongoing technical support and case consultation services
- Practice marketing materials to educate your patients
- Assistance with insurance pre-authorisation and coding
- Regular updates on clinical advances and product innovations
Whether you're ready to place your first order or simply want to learn more about how amniotic membrane therapy could benefit your patients, our team is here to assist. We understand that adopting new technologies requires careful consideration, and we're committed to providing all the information and support you need to make informed decisions.
Speak directly with our clinical specialists to discuss specific cases, explore product selection, and receive personalised recommendations for your practice needs
Experience the quality and convenience of our amniotic membrane products firsthand through our clinical evaluation programme for qualified practitioners
Participate in hands-on surgical workshops or virtual training sessions led by expert surgeons with extensive experience in amniotic membrane applications
The future of ocular surface therapy is here, combining nature's regenerative wisdom with modern biomedical engineering. Akriti Ophthalmic stands ready to partner with you in bringing these transformative treatments to the patients who need them most. Together, we can continue advancing the field of regenerative ophthalmology, one healed eye at a time.
Akriti Ophthalmic—Advancing vision through regenerative innovation
We value your inquiries and are dedicated to providing comprehensive support. Whether you have general questions, need technical assistance, or are interested in partnership opportunities, our team is ready to connect with you. Reach out through any of the channels below, and let's advance ocular care together.
Need information about our products or services? Our team is available to assist you.
Phone:
+1 216 239 9880
+91 9849193447
Visit us or send mail to our corporate office.
Akriti Ophthalmic Pvt Ltd
M34, M35, M36, Medical Devices Park
Sultanpur Village, Patancheru Mandal
Hyderabad – 502319, Telangana, India
North America:
Akriti Ophthalmic USA LLC
401 Ryland St, Ste 200a, Reno, NV, 89502, USA
Smart Technology LLC
12325 Lake Shore Blvd Cleveland OH,44108, USA
Business Hours:
Monday - Friday: 9:00 AM - 6:00 PM (IST)
Saturday: 10:00 AM - 2:00 PM (IST)
Sunday: Closed
Explore more about Akriti Ophthalmic and our solutions.
Stay updated with our latest news, events, and insights.
Locate our office in Hyderabad, Telangana, India.
Transforming ocular surface treatment through innovative regenerative medicine